Deals channel feed

Hi­ber­na­tion re­search could lead to new weight loss med­i­cines — could it al­so help as­tro­nauts in space?

Last year
R&D

Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

Last year
Financing

Sun Phar­ma to buy out the rest of Taro's own­er­ship

Last year
Pharma

Up­dat­ed: Ven­ture cap­i­tal firm Gen­er­al Cat­a­lyst is buy­ing an Ohio-based health sys­tem

Last year
Health Tech

Deer­field adds an­oth­er aca­d­e­m­ic part­ner in $130M Wash­ing­ton Uni­ver­si­ty pact

Last year
Startups

Eval­u­ate buys fore­cast­ing group to build out pre­dic­tion soft­ware and ser­vices

Last year
Marketing

No­var­tis re­port­ed­ly backs off ac­qui­si­tion of Cy­to­ki­net­ics – WSJ

Last year

Emer­gent nabs US gov­ern­ment con­tract of up to $235.8M for an­thrax vac­cine 

Last year
Manufacturing

BioN­Tech pays $20M up­front for two mon­o­clon­al an­ti­bod­ies from Chi­na's WuXi Bi­o­log­ics

Last year
China

Co­herus ex­its TIG­IT deal with Jun­shi, three months af­ter Sur­face On­col­o­gy buy­out

Last year
R&D

#JPM24 quick hits: Vibe check; Maze’s next turn; AI at phar­ma com­pa­nies + more

Last year
AI
Pharma

Mer­ck is eye­ing new im­munol­o­gy deals, chief med­ical of­fi­cer says: #JPM24

Last year

No­var­tis CEO plays down Cy­to­ki­net­ics buy­out ru­mors in CN­BC in­ter­view

Last year

Lan­theus hands Per­spec­tive Ther­a­peu­tics $28M up­front to ex­pand its ra­dio­phar­ma op­tions

Last year
Manufacturing

Ather­sys files for Chap­ter 11 bank­rupt­cy, sells every­thing to part­ner Healios

Last year
Cell/Gene Tx

GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

Last year
China
Pharma

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
R&D
Pharma

Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

Last year
Pharma

Up­dat­ed: No­var­tis close to ac­quir­ing Cy­to­ki­net­ics af­ter biotech's PhI­II heart dis­ease win — WSJ

Last year

Ve­r­a­cyte to buy C2i Ge­nomics for up to $95M, in­cludes $70M up­front

Last year
Diagnostics

J&J makes $2B push in­to AD­Cs with Am­brx buy­out in on­col­o­gy deal spree: #JPM24

Last year
Pharma

Mer­ck brings Har­poon Ther­a­peu­tics and its PhI/II T cell en­gager in­to the fold for $680M

Last year

No­var­tis li­cens­es two car­dio­vas­cu­lar RNAi drugs from Chi­nese biotech for $185M up­front

Last year
R&D

No­var­tis strikes $250M buy­out for Mer­ck Serono spin­out's au­toim­mune 'pipeline-in-a-drug'

Last year
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times